| dc.contributor.author | Vielnascher, Raimund M. | |
| dc.contributor.author | Pfeiffer, Andrea | |
| dc.date.accessioned | 2023-01-02T23:42:26Z | |
| dc.date.available | 2023-01-02T23:42:26Z | |
| dc.date.issued | 2016 | |
| dc.identifier.uri | https://clinicaltrials.gov/ct2/show/NCT02996890 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/3154 | |
| dc.description.abstract | Double blinded, randomized, placebo-controlled, dose finding, multi-center, phase 1 trial in 48 healthy volunteer subjects.
After completion of screening procedures, the subjects are randomized to one of four treatment groups (different dosage strengths and placebo) All subjects will receive study treatment at day 0 and will return on day 28. Subjects randomized to treatment groups with two vaccinations will receive a second treatment at day 28.
Subjects will return on day 56 for the final visit. | en_US |
| dc.language | English | en_US |
| dc.subject | Zika Research Project | en_US |
| dc.subject | Zika Virus | en_US |
| dc.subject | Immunogenicity, Vaccine | en_US |
| dc.title | Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability | en_US |
| eihealth.country | Others | en_US |
| eihealth.category | Epidemiology and epidemiological studies | en_US |
| eihealth.type | Research protocol information | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
| dc.relation.ispartofjournal | Clinical Trials | en_US |
